Skip to content

Assessment of Endocan Serum Levels in Patients With Behcet Disease

Assessment of Endocan Serum Levels in Patients With Behcet Disease: Relation to Clinical Parameters and Disease Status

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03853135
Enrollment
84
Registered
2019-02-25
Start date
2019-02-27
Completion date
2019-12-16
Last updated
2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behçet

Keywords

Behçet disease, endocan

Brief summary

The aim of our study was to assess serum endocan levels in patients with Behcet disease and to correlate it with various disease clinical and laboratory parameters of disease activity as well as carotid intima media thickness.

Detailed description

This study will be carried out on two groups: • Group (I): Forty two patients diagnosed to have Behcets disease fulfilling the International Criteria for BD . Group (II): including 42 age and sex matching healthy volunteers as control group. (A) Clinical evaluation 1. Complete history taking. 2. Thorough clinical examination including opthalmologic evaluation . 3. Disease activity using The Behcet's disease current activity form (BD-DAF) . (B) Laboratory assessment: All patients will be subjected to the following measurements: 1. ESR 2. CRP 3. CBC 4. liver and kidney function tests d) Serum Endocan level e)triglycrides f) cholestrol C) carotid intima media thickness

Interventions

DIAGNOSTIC_TESTmeasurement of serum endocan

measurement of serum levels of endocan

Sponsors

Benha University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* patients with Behcets disease fulfilling the International Criteria for BD .

Exclusion criteria

* infection * malignancy * other connective tissue disease * chronic liver disease * chronic kidney disease * Diabetes mellitus * hypertension * hyperlipidemia

Design outcomes

Primary

MeasureTime frameDescription
the Behcet's disease current activity form (BDCAF): through study completion, an average of 6 monthsOne point is given to the presence of different organ involvement over the 4 weeks prior to assessment as follows: headache, mouth ulcers, genital ulcers, skin lesions , joint involvement , gastrointestinal symptoms , eye involvement , nervous system involvement , and major vessel involvement.The total score will be out of 12 and higher score indicates worse outcome. we will assess the relation between serum endocan level and BDCAF
Erythrocyte sedimentation rate (ESR): through study completion, an average of 6 monthsESR measured in mm/1st hour by westergren method. we will assess the relation between serum endocan level and ESR
C reactive protein (CRP): through study completion, an average of 6 monthsCRP measured in mg/L using nephlometry. we will assess the relation between serum endocan level and CRP
carotid intima media thickness: through study completion, an average of 6 monthsColor Doppler ultrasonography was performed for both common carotid arteries in a longitudinal orientation and measured with millimeter

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026